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AbstrACt
Objectives Treatment burden is the workload of 
healthcare for people with long-term conditions (LTC) and 
its impact on well-being. A method of measurement is 
required to identify those experiencing high burden and 
to measure intervention efficacy. Our aim was to identify, 
examine and appraise validated patient-reported measures 
(PRMs) of treatment burden in stroke. Here, stroke serves 
as an exemplar LTC of older adults.
Design A systematic review of published studies 
that describe the development and validation of PRMs 
measuring treatment burden in stroke survivors.
Data sources We searched MEDLINE, Embase, CINAHL 
and PsycINFO electronic databases.
Eligibility criteria Studies published between January 
2000 and 12 April 2019 inclusive, in English language. 
No restrictions were set based on clinical setting or 
geographical location.
Data extraction and synthesis Screening, data 
extraction and quality appraisal were conducted by 
two independent reviewers. Content of the PRMs was 
compared with a published taxonomy of treatment burden. 
Quality appraisal was conducted using International 
Society for Quality of Life Research standards.
results From 3993 articles, 6 relevant PRMs were 
identified: 3 were stroke specific: The Satisfaction with 
Stroke Care questionnaire; The Stroke Patient-Reported 
Outcome Measure and The Barriers to Physical Activity 
after Stroke scale. Three were generic but validated 
in stroke: The WHO Quality of Life-100; The Patient’s 
Questionnaire on Participation in Discharge Planning 
and The Chao Perception of Continuity scale. None 
comprehensively measured treatment burden. Examples 
of omitted burdens included developing coping strategies, 
managing finances and returning to driving. The most 
notable issue regarding quality appraisal was that three 
PRMs lacked any underpinning qualitative research 
relevant to the sample.
Conclusion There is a need to develop a comprehensive 
PRM of treatment burden for use in stroke, with potential 
for use in other older populations.
IntrODuCtIOn
Stroke is a common condition of older adults; 
in Europe, the incidence of stroke increases by 
a factor of 100 between the ages of 40 and 80 
years.1 Stroke treatments, particularly newer 
rehabilitative therapies, are often complex 
with multiple interacting components or 
people involved in their delivery. Multidis-
ciplinary therapy and early discharge from 
hospital are now recommended in guidelines, 
and these are becoming more commonplace 
in practice.2 3 Engaging with and accessing 
such treatments, however, can demand 
considerable time and effort from stroke 
survivors, and this can be difficult for those 
who are older or frail.
Our previous qualitative research and 
systematic review demonstrated that people 
who have had a stroke can feel overwhelmed 
by managing their recovery and that this is 
exacerbated when health services are frag-
mented and lacking in a person-centred 
approach.4 5 Treatment burden is defined 
as the workload of healthcare for people 
with long-term conditions and its impact 
on well-being.5 6 It is becoming increasingly 
recognised by governing bodies and clinical 
guidelines as an important barometer of 
quality of care requiring attention.7 Health-
care workload encompasses all tasks relating 
to health including those recommended by 
health professionals and those required to 
maintain or improve health status.8 Through 
our previous research, we created a taxonomy 
of treatment burden in stroke and a concep-
tual model,4 5 the latter is shown in figure 1. 
Our research showed that treatment burden 
strengths and limitations of this study
 ► The first systematic review to examine patient-re-
ported measures of treatment burden in stroke, an 
important aspect of patient care.
 ► Thorough literature search of four major electronic 
databases and reporting as per Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis 
guidelines.
 ► Exclusion of non-English language papers and 
publication pre-2000 (the latter due to the rapidly 
evolving nature of stroke management over recent 
decades).
 ► Treatment burden is a recently recognised concept 
influencing quality of care and quality of life, making 
literature searches challenging.
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Figure 1 Conceptual model of stroke treatment burden. The arrows represent the possible pathways between components 
that stroke patients may follow. The ‘enacting management strategies’ component has four subcomponents. Reproduced with 
permission from Plos MED4 (creative commons Attribution-Non-commercial 4.0 license).
is not purely dependent on volume of healthcare work; 
the way that services are planned, delivered and co-or-
dinated also influences the perceived burden felt by an 
individual.5 For example, poor co-ordination or commu-
nication between healthcare providers can result in dupli-
cation or omission of important aspects of care. Capacity 
to manage healthcare workload will vary greatly between 
individuals due to personal abilities and circumstances; 
therefore, two people with the same treatment workload 
may cope very differently.5 8
Treatment burden is important because it may reduce 
quality of life and result in non-adherence to recom-
mended treatments, resulting in suboptimal health-re-
lated outcomes and wasted health service resources.9 
For example, intentional and non-intentional non-ad-
herence to medications may result because of an exces-
sively complex or poorly planned medication regimen.10 
Consideration of treatment burden is particularly 
important in older people who may have a decreased 
ability to self-manage health due to physical, cognitive 
and emotional difficulties. To date, treatment burden 
has been under-researched4 11 and may not be adequately 
considered by clinicians involved in the provision of care 
for older people with long-term conditions.
Stroke can be used as an exemplar long-term condi-
tion for describing treatment burden. It is common in 
older adults,1 often occurs in the context of other comor-
bidity12 and can result in complex physical and cognitive 
impairments.13 In previous work, we created a concep-
tual model of treatment burden in stroke through qual-
itative systematic review and analysis of interviews with 
stroke survivors.4 5 This provided important insights into 
the lived experience of treatment burden in this group 
and highlighted the need for a method to quantify this 
burden. There are many potential applications of a tool 
that measures treatment burden. It could enable clini-
cians to identify those experiencing high levels of burden 
who may need additional support with self-management. 
It could facilitate inclusion of treatment burden as an 
outcome in clinical trials of stroke therapies alongside 
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measures of efficacy to ascertain if treatments are not only 
effective, but manageable in older, frailer patients in the 
‘real world’. Lastly, measurement of treatment burden 
would allow analysis of the effectiveness of interventions 
aimed at decreasing burden.
Treatment burden is experienced on an individual 
level; therefore, a patient-reported measure (PRM) is the 
best approach to measurement. A PRM is a report of the 
patient’s health experience or experience with health-
care that comes directly from the patient, without inter-
pretation of the response by anyone else.14 It is a common 
and useful way to measure experiences or outcomes 
that require information directly from the patient, for 
example, health-related quality of life or satisfaction 
with health services. To help clinicians and researchers 
select which PRMs to use in a given setting, The Inter-
national Society for Quality of Life Research (ISOQOL) 
has published a set of standards that can be used in the 
quality appraisal of PRMs.14
The aim of this systematic review is to collate and appraise 
published, validated PRMs of treatment burden in stroke, 
including discrete portions of PRMs that measure burden 
(eg, scales, scorable single items). We were particularly 
interested in content of the tool, the extent to which the 
PRMs aligned with our previously developed conceptual 
model of treatment burden in stroke4 5 and the quality of 
the supporting research.14
MEthODs
We followed Preferred Reporting Items for Systematic 
Reviews and Meta-Analysis (PRISMA)15 guidance in the 
design, conduct and reporting of our review (online 
supplementary appendix 1). A protocol was developed 
and is available at https://www. crd. york. ac. uk/ pros-
pero/. All aspects of screening and data extraction were 
performed by two independent reviewers (KIG, MD, TJQ, 
LK, JE, NJ, DTE) with recourse to a third arbitrator as 
necessary (FSM).
searching strategy
An initial scoping search was carried out to identify 
relevant terms and phrases, which would be used in the 
formal electronic search. This consisted of a prelimi-
nary search of personal files; MEDLINE via Ovid and 
the use of the ‘related articles’ function in PubMed. A 
formal search strategy was then created with an informa-
tion scientist (PJE). We used a concept-based approach 
to design the search syntax, using validated search filters 
where available. The concepts were stroke, treatment 
burden and PRM. The full search strategy can be found 
in online supplementary appendix 2. As ‘patient-reported 
measure’ is not a recognised subject heading, ‘patient-re-
ported outcome measure’ was used and in addition 
‘patient reported’ was entered as a textword or subject 
heading or author keyword. Databases searched were 
as follows: MEDLINE (Ovid), Embase (Ovid), CINAHL 
(EBSCO) and PsycINFO (Ovid) from first January 2000 
up to and including 12 April 2019. PRMs predating 2000 
were deemed to be irrelevant to the current experiences 
of stroke survivors due to considerable changes in stroke 
management over recent decades.
screening
Papers found were uploaded to a web-based systematic 
software programme DistillerSR (Evidence Partners) to 
facilitate screening and data extraction. Inclusion criteria 
are shown in online supplementary appendix 3.
Consistent with a prior systematic review of treatment 
burden measures,11 potentially relevant scales were 
assessed at the level of individual items or domains. Items 
in each measure were scrutinised to ascertain if they 
were consistent with the definition of treatment burden 
outlined in the inclusion criteria (which is in line with the 
taxonomy of treatment burden and conceptual model 
created in our previous research).4 5 If less than 50% of 
items in the PRM reflected treatment burden, then it was 
excluded. An exception to this was the presence of an 
independently scorable item or subscale that was deemed 
relevant, regardless of size. If a study had used a poten-
tially relevant PRM but no information on development 
or validation was given in that paper, then the original 
development paper was sought and examined. If the 
original development paper was published pre-2000 but 
the PRM had been used in a published study after that 
date, then the PRM was included. References of included 
papers were scrutinised for relevant articles and the above 
process repeated until no new titles were found.
Data extraction and evidence synthesis
The data extraction and quality appraisal form is provided 
in online supplementary appendix 4. Data extracted 
were as follows: descriptive data about the study (eg, 
sample size and details of participant characteristics), 
items relating to treatment burden and information on 
PRM development or validation including psychometric 
testing. Content of the items on treatment burden was 
mapped to the taxonomy of treatment burden created 
in our previous work.4 5 This was undertaken to ascer-
tain which aspects of treatment burden were included 
in the PRMs and to scrutinise if any burdens were 
omitted. Quality appraisal was conducted using ISOQOL 
standards14 as a reference. ISOQOL standards include 
whether the PRM was developed from underpinning 
qualitative research; reliability (how much it is free 
from measurement error); content validity (whether it 
measures what is relevant and important to the patient); 
construct validity (whether it measures what it purports 
to measure); responsiveness (whether it can detect 
changes over time); interpretability of scores (whether 
scores are meaningful to those using it) and patient and 
investigator burden (how difficult it is to use). We did 
not create a summative quality score and did not exclude 
papers due to perceived risk of bias; rather it served as a 
point of discussion.
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Figure 2 Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flow chart. PRM, patient-reported 
measure.
Patient and public involvement
The Research Advisory Group that guides this programme 
of research includes four stroke survivors or carers of 
stroke survivors. Their input has helped to guide the 
aims, objectives and methods of this study. Additionally, 
the results of this study were presented to three individ-
uals with cardiovascular disease and discussed in a focus-
group setting, which informed our discussion in the 
paper.
rEsults
screening
The PRISMA diagram of included studies is shown in 
figure 2. The database search yielded 3993 articles, of 
which 184 were retrieved for full-text review. The text of 
a further 21 papers, which were identified through refer-
ence list searching or were the original validation studies 
of PRMs identified within the full text papers, was also 
fully reviewed.
Identified PrMs
Six papers were identified that each described the 
development or testing of a relevant PRM16–21 and were 
included in the review (table 1).
The Satisfaction with Stroke Care (SASC) question-
naire16 was developed to measure stroke survivor’s 
satisfaction with inpatient and outpatient health and 
social care services; 12 out of 13 items measure treatment 
burden. This PRM was originally developed and vali-
dated in a sample of stroke survivors. The Stroke Patient 
Reported Outcome Measure (Stroke-PROM)17 was devel-
oped for use as an outcome measure in stroke drug trials 
and measures the effects of stroke and its treatments on an 
individual. Only 4 out of 46 items are relevant to treatment 
burden, but this was an independently scorable domain 
on satisfaction with treatments. This PRM was developed 
and validated in a sample of stroke survivors. The Barriers 
to Physical Activity after Stroke scale (BAPAS)18 was 
developed to measure the perceived barriers to regular 
physical exercise after a stroke. It was developed and 
validated in stroke survivors, and 7 out of 14 items were 
deemed relevant to treatment burden. The other three 
measures were originally developed in non-stroke popula-
tions and subsequently validated in stroke survivors. The 
WHO Quality of Life-100 (WHOQOL-100)19 is aimed at 
measuring quality of life and 4 out of its 100 items are 
relevant; they measure accessibility and quality of health 
and social care and constitute an independently scorable 
domain. The Patient’s Questionnaire on Participation 
in Discharge Planning (P-QPD)20 measures perceived 
patient involvement in the discharge planning process, 
all items are relevant to treatment burden, and all focus 
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Table 2 Our taxonomy of treatment burden in stroke
Type of treatment burden Healthcare workload Care deficiency
Making sense of stroke 
management and planning care
Understanding symptoms, investigations, treatments, 
risk factors.
Information gathering.
Taking responsibility for health management.
Goal setting and prioritising.
Problem solving.
Managing uncertainty.
Maintaining motivation.
Developing coping strategies.
Coping with negative emotions.
Lack of information provision and poor 
signposting.
Information hard to understand.
Poorly timed information.
Not enough verbal information.
Information not tailored to individual.
Lack of support with care planning.
Interacting with others Seeking advice or help from health and social care 
professionals.
Gaining emotional and practical support from friends, 
family, fellow patients.
Strained relationships due to treatments.
Protecting carers from stress.
Dealing with stigma, for example, of walking aids.
Misdiagnosis.
Paternalism from HPs.
Lack of empathy from HPs.
Mismatch in ideas between patient and 
HP.
Poor access to a GP.
Poorly co-ordinated care.
Poor continuity.
Poor communication from GP.
Enacting management strategies Undergoing acute care.
Inpatient rehabilitation.
Discharge process.
Community rehabilitation.
Attending outpatient appointments/therapies.
Taking medications.
Risk factor modification.
Managing comorbidities.
Adaptations to home.
Organising and receiving home care.
Return to driving and employment.
Using mobility aids.
Managing finances.
Paying for treatments.
Enacting coping strategies.
Using alternative therapies.
Waiting times for inpatient tests.
Unpleasant ward.
Poorly supported discharge.
Poor GP follow-up.
Lack of help with transport to 
appointments.
Complicated medication regimens.
Poor access to home adaptations and 
walking aids.
Substandard home care.
Poor access to driving assessment.
Complicated benefits system.
Lack of psychological support and 
support groups.
Reflecting on management Attending review appointments.
Joint healthcare decisions with HPs.
Reflecting on progress.
Deciding on adherence to HP advice.
Keeping up to date with new treatments available.
Managing worry about another stroke.
Poor short-term follow-up for milder 
cases.
Poor long-term follow-up for all.
Aspects of treatment burden not included in any of the PRMs found are shown in italics.
GP, general practitioner; HP, health professional; PRM, patient-reported measure.
on the discharge process. The Chao Perception of Conti-
nuity scale (Chao-PC)21 has 23 items; 17 of which measure 
treatment burden, all items focus on continuity of care.
Details of the participants included in each study are 
given in online supplementary appendix 5. Five of the 
studies reported a mean age over 60 years,16 18–21 the 
other stated that 48% were between 45 and 65 years 
and that 40% were 65 years or over.17 Two studies were 
conducted in the UK (SASC and Chao-PC),16 21 both were 
community based with a majority of white participants. 
The other studies were conducted in France (BAPAS),18 
China (Stroke-PROM),17 Sweden (P-QPD)20 and Turkey19 
(WHOQOL-100). All studies included a balanced mix of 
men and women. Level of participant education varied 
between studies, the Chinese sample had the highest17 
and one of the UK samples had the lowest.21
Content of the PrMs
Table 2 shows the aspects of treatment burden included 
in and missing from the PRMs found. All aspects of treat-
ment burden found within the included PRMs fell inside 
our previously published conceptual framework and 
taxonomy.
Quality appraisal
A detailed account of quality appraisal is given in table 3. 
The three PRMs that were developed in stroke popu-
lations (SASC, Stroke-PROM and BAPAS)16–18 were 
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developed from qualitative work relevant to the sample, 
that is, in stroke survivors. The WHOQOL-100 had been 
originally developed from qualitative work undertaken in 
non-stroke populations and did not include any qualita-
tive research examining stroke survivors’ experiences. It 
was unclear if the Chao-PC or the P-QPD had been devel-
oped from any underpinning qualitative work with stroke 
survivors; however, development of the Chao-PC was 
underpinned by Banahan’s conceptual model of conti-
nuity of care.22 23
Regarding reliability, all PRMs had been tested for 
internal consistency and all were found to be suitably 
reliable (Cronbach’s alpha >0.70). Only two studies 
provided information on test-retest reliability (SASC and 
BAPAS).16 18 The SASC study assessed this by weighted 
kappa in a sample of 21 patients who repeated the PRM 
2 weeks after the original mailing.16 Eleven out of the 13 
items had a weighted kappa ≥0.3 and the authors reported 
that cut-off as acceptable. The BAPAS study repeated the 
measure in 21 participants after 4–6 days and found good 
reproducibility with an intraclass coefficient of 0.9.18 
However, authors note the short interval between test and 
retest, therefore the possibility of recollection bias.
Content validity had been assessed in all studies, 
although in the case of the WHOQOL-10019 this was not 
with stroke survivors and the SASC16 had not been tested 
face-to-face. All studies had assessed construct validity 
using various methods including factor analysis, correla-
tions with other PRMs and known-group validity. Results 
are detailed in table 3.
None of the studies had tested for responsiveness to 
change, but this was deemed appropriate as none were 
measuring outcomes longitudinally.
Regarding interpretability, all papers described the 
meaning of high and low scores but only one described a 
cut-off (SASC).16
Three studies (SASC, Stroke-PROM and Chao-
PC)16 17 21 reported that they assessed participant burden 
by analysing response rates; the two with high response 
rates were deemed to have low burden (SASC, Stroke-
PROM)16 17 and the other with a low response rate 
(Chao-PC) was deemed not easily transferable to a UK 
population without further modification due to the struc-
ture and content of its items.21 Two studies reported time 
to complete the measure (Stroke-PROM and BAPAS).17 18 
None assessed investigator burden, that is, ease of use for 
the researcher using the PRM.
DIsCussIOn
PrMs found
We found six PRMs that measure treatment burden in 
stroke. All had been tested in older stroke survivors in a 
mix of hospital and community settings within developed 
countries. None of the PRMs found had been developed 
to comprehensively evaluate treatment burden and none 
of the included studies were aimed at doing so. Rather, 
they were aimed at assessing related concepts or narrow 
aspects of treatment burden. One PRM, which was devel-
oped before treatment burden had been conceptual-
ised in the medical literature, was aimed at measuring 
patient satisfaction (SASC),16 and this covered the most 
aspects of treatment burden out of the PRMs found, 
however, many treatment burdens were missing. Three 
PRMs focused on important but limited aspects of treat-
ment burden: barriers to participation in physical activity 
(BAPAS),18 continuity of care (Chao-PC)21 and partic-
ipation in discharge planning (P-QPD).20 The other 
two (WHOQOL-100 and Stroke-PROM)17 19 are longer 
measures that included a small minority of items that 
were relevant to the issue of treatment burden and inde-
pendently scorable. In summary, none of the published 
PRMs comprehensively measured treatment burden in 
stroke.
During quality appraisal, the most notable weakness 
was that the three studies that involved validation of 
PRMs originally developed in non-stroke populations 
(Chao-PC, P-QPD, WHOQOL-100)19–21 did not describe 
any qualitative work underpinning their use in stroke 
survivors. Additionally, the lack of assessment of content 
validity or consideration of feasibility of the WHOQOL-
100 results in uncertainty about whether this long 
100-item measure is suitable in a stroke population who 
are typically older and potentially cognitively impaired, 
frail or easily fatigued. Only one PRM (SASC)16 provided 
a cut-off score, this was for ‘satisfactory treatment’. None 
of the studies were longitudinal therefore none assessed 
responsiveness; however, testing of this would be required 
if longitudinal measurement was an intended future use 
of the PRM, such as in a clinical trial. One measure (Chao-
PC)21 was deemed by the authors as unsuitable for use in 
a UK population due to the structure and content of the 
items. For example, items did not distinguish between 
primary and secondary care and so could be confusing 
to a UK patient.
strengths and limitations
Our search was limited to English-language papers, 
which could be viewed as a limitation, although there 
is increasing evidence that this may have little effect.24 
Exclusion of papers published pre-2000 could also be 
viewed as a limitation; however, this was chosen due to 
the rapidly evolving nature of stroke management over 
recent decades. One paper published before 2000 was 
included because the PRM identified had been used in 
subsequent studies after that date.25 Searching for papers 
that examine treatment burden is challenging because it 
is a relatively new concept that is multifaceted. To combat 
this, we clearly defined treatment burden prior to the start 
of our review based on our previous qualitative work.4 5
how results fit in with current literature and future research
Treatment burden is a relatively new concept in the 
medical literature, with robust qualitative work giving us 
a better understanding of the patient experience of this 
phenomenon in stroke and other patient groups.4–6 26 27 
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Aspects of care that stroke survivors describe as particu-
larly burdensome include information provision about 
stroke treatments, care co-ordination and the process of 
transitioning from hospital into the community.4 5 These 
are examples of areas that would benefit from measure-
ment and intervention to lessen treatment burden. 
Despite this, we still need to understand more about the 
relationship between treatment burden and health-re-
lated outcomes; how burden changes over the patient 
journey and whether we can lessen treatment burden 
through altering the way that healthcare is provided. 
To examine these areas, quantification of treatment 
burden is required, yet this is not straightforward. Treat-
ment burden is more than simply healthcare work-
load, it is a complex interplay of healthcare systems, 
individuals and their social networks that results in a 
feeling of encumbrance if demand outweighs personal 
resources.5 8 This has the potential to lead to disengage-
ment from health services, wasted resources and wors-
ening health outcomes, particularly in vulnerable groups 
such as those who are older, frail, socioeconomically 
deprived or socially isolated.28
Treatment burden has received attention from 
researchers interested in individual conditions29–32 and 
from those interested in studying people with multiple 
long-term conditions.6 PRMs have recently been devel-
oped for use in the latter population.33–35 There is overlap 
between these generic treatment burden PRMs and our 
taxonomy of treatment burden in stroke; however, many 
stroke-specific burdens are not represented in the generic 
measures, such as robotic upper limb neurorehabilita-
tion, speech and language therapy, management of visual 
problems and vocational rehabilitation. There is good 
evidence that stroke survivors obtain better health-related 
outcomes in treatment pathways designed specifically for 
stroke survivors,36 and therefore, some of their healthcare 
experiences are likely to be different. In this systematic 
review, we chose to exclude PRMs that have not been vali-
dated in stroke survivors because current guidance for 
PRM selection indicates that it is desirable that chosen 
PRMs be validated in a sample relevant to the popula-
tion in question.14 This means that PRMs not developed 
for use in stroke specifically may not fully represent all 
treatment burdens encountered by stroke survivors. Addi-
tionally, stroke survivors are typically older individuals 
who may have cognitive impairment, visual difficulties or 
aphasia that can make completion of a PRM challenging. 
It is vital that when PRMs are developed for use in older 
populations that careful attention is paid to usability in 
this group.
In conclusion, we found no comprehensive PRMs of 
treatment burden that had been validated in a stroke 
population. Further research to develop and validate 
a new PRM of treatment burden in stroke would be 
important to enable new insights into the quality of care 
and quality of life of stroke survivors. Such a tool could 
also be of value for use in other older populations with 
similar healthcare challenges.
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